Regeneron jumps as Q1 2026 beat and fresh $3B buyback offset Eylea worries
REGN•Regeneron shares rose after the company reported Q1 2026 results with non-GAAP EPS of $9.47 on about $3.6 billion of revenue, topping expectations and showing 19% revenue growth. Investors also highlighted a newly authorized additional $3.0 billion share repurchase program disclosed in April 2026.
1. What’s moving REGN today
Regeneron Pharmaceuticals (REGN) is trading higher as investors react to the company’s Q1 2026 earnings update and capital-return headlines. The quarter delivered an earnings-and-revenue beat (non-GAAP EPS of $9.47 and roughly $3.6B in revenue), while filings also highlighted a board authorization in April 2026 for an additional $3.0 billion share repurchase program—supporting the stock after recent volatility.
2. The earnings print: growth led by key franchises
Management framed the quarter as a strong start to 2026, with commercial momentum centered on large brands including Dupixent and EYLEA HD. The market’s focus has been whether Regeneron can sustain growth as it manages the transition within its ophthalmology franchise, while continuing to expand immunology and oncology revenue streams. The earnings beat helped re-anchor sentiment around the near-term financial trajectory.
3. Capital return catalyst: additional $3.0B buyback authorization
Alongside results, investors are leaning into Regeneron’s stepped-up shareholder return plan. An SEC filing for the March 31, 2026 quarter states the board authorized an added $3.0 billion share repurchase program in April 2026, on top of previously authorized programs, reinforcing an ongoing willingness to deploy cash toward buybacks and support per-share metrics.
4. What investors will watch next
After the post-earnings move, attention shifts to durability of Dupixent-driven growth, execution in the EYLEA-to-EYLEA HD transition, and any further clarity on regulatory timelines tied to product lifecycle management in ophthalmology. Traders will also monitor the pace of repurchases under the expanded authorization and whether management commentary points to improving trends in the eye franchise over the next quarters.
